The DOI matches its Crossref record; 96 of the 99 references it cites were found in a registry or an index.
Treatment of depression with atypical features: A meta-analytic approach
Abstract
The present meta-analysis addressed the empirical evidence regarding the treatment of major depression with atypical features. The superiority of monoamine oxidase inhibitors (MAOIs) compared with other antidepressants in the treatment of major depression with atypical features has been frequently reported. According to the CONSORT Statement, studies included in our meta-analysis had to meet several criteria, especially a double-blind, controlled condition and an operational diagnosis according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-III or DSM-IV criteria, respectively. Four databases for research-based evidence were used in a systematic review: Medline, Embase, Psyndex and PsycInfo. Only eight publications met inclusion/exclusion criteria, resulting in 11 comparisons. Our results contrast an effect size of 0.45 (95% confidence interval) for a comparison of MAOIs vs. placebo with an effect size of 0.02 (95% confidence interval: - 0.10-0.14) for a comparison of MAOIs vs. selective serotonin reuptake inhibitors. The effect size for MAOIs vs. tricyclic antidepressants was 0.27 (95% confidence interval: 0.16-0.42). MAOIs may be more effective for atypical major depressive disorder than tricyclic antidepressants. Most clinical research has been conducted on irreversible MAOIs. Additional studies testing more recently developed antidepressants (including reversible MAOIs) with an improved safety profile would be warranted. The available data are insufficient for a direct comparison between MAOIs and selective serotonin reuptake inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Individuals with atypical depression often have a more unrelenting course of depression [13], in part because they show a poorer response to antidepressants [14].”
From The menace of obesity to depression and anxiety prevalence (2022) · cites this paper as [14]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Statistical Power Analysis for the Behavioral Sciences
Muller, K. E., & Cohen, J. (1989) · Technometrics · doi:10.2307/1270020 · Cited by 99,603
Statistical power analysis for the behavioral sciences
Cohen, J. (1990) · Computers Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,417
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
Statistical Power Analysis for the Behavioral Sciences (2nd ed.).
Lachenbruch, P. A., & Cohen, J. (1989) · Journal of the American Statistical Association · doi:10.2307/2290095 · Cited by 37,421
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
(1976) · Medical Entomology and Zoology · Cited by 8,899
Meta-Analytic Procedures for Social Research
Rosenthal, R. (1991) · doi:10.4135/9781412984997 · Cited by 4,635
Research works printed but not linked: 10
- Cairoli, 1987, Considerations on the utility of an atypical bicyclic antidepressive (Viloxazine) administered intravenously in depressed patients: plasma levels, tolerance, and clinical response, Psichiatria e Psicoterapia Analitica, 6, 341
- Cironi, 1992, Evaluation of the efficacy and tolerance of fluoxetine in atypical depression, Rivista di Psichiatria, 27, 53
- De Leo, 1985, S-adenosyl-l-methionine (SAMe) in clinical practice: preliminary report on 75 minor depressives, Current Therapeutic Research, 37, 658
- Ginsberg, 2003, Chromium picolinate treatment of atypical depression, Primary Psychiatry, 10, 23
- Gomes de Matos, 2000, Venlafaxine in atypical depression, Jornal Brasileiro de Psiquiatria, 49, 185
- Hayano, 1994, Trazodone as an antidepressant (1)—the background factor of depressive patients, Journal of the Wakayama Medical Society, 45, 469
- Heinze, 1989, Antidepressive efficacy and tolerance of moclobemide: a monoaminooxidase reversible inhibitor, Salud Mental, 12, 17
- Salorio, 1997, Electroconvulsivant therapy in the treatment of atypical depression, Folia Neuropsiquiatrica, 32, 131
- Sovner, 1996, Ketoconazole therapy for atypical depression, Journal of Clinical Psychiatry, 57, 227
- Stratta, 1992, A double-blind study comparing fluoxetine with imipramine in the treatment of atypical depression, Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali, 116, 148
Cited by
Sorted by citations
Items 101–159 of 159
Monoamine Oxidase Inhibitors in Depressive Disorders
Meyer, J. H., Matveychuk, D., Holt, A., Santhirakumar, A., & Baker, G. B. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_98 · Cited by 2
MacKinnon, D. F., & Chen, L. N. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_20-1 · Cited by 2
Sung, S.-H., Park, S., Han, K., Won, E., Lee, H.-Y., Koo, J.-W., Paik, J., Lee, K., Jeon, H. J., Lee, M., et al. (2013) · 신경정신의학 · doi:10.4306/jknpa.2013.52.5.372 · Cited by 2
Introduction: new directions in the treatment of atypical depression.
Thase, M. E. (2007) · PubMed · Cited by 2
Für jeden Patienten den optimalen Wirkstoff finden
Lieb, M., Rupprecht, R., & Baghai, T. C. (2012) · NeuroTransmitter · doi:10.1007/s15016-012-0565-x · Cited by 2
Getting Published and Having an Impact: Turning Rehabilitation Research Results Into Gold
Brown, M., & Gordon, W. A. (2008) · Cited by 2
Treatment History Characteristics Associated With Use of Isocarboxazid
Holm, M., Larsen, J., Ishtiak‐Ahmed, K., Speed, M. S., Gasse, C., & Østergaard, S. D. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001505 · Cited by 2
Psychopharmacology for Pediatric Depressive Disorders
Rengasamy, M. L., Shalev, A., & Birmaher, B. B. (2024) · Springer eBooks · doi:10.1007/978-3-031-57472-6_16 · Cited by 2
PSYCHOPHARMACOLOGY COLUMN WHY CHOOSE SELEGILINE TRANSDERMAL SYSTEM FOR REFRACTORY DEPRESSION?
Tobin, M. L. (2007) · Issues in Mental Health Nursing · doi:10.1080/01612840601096461 · Cited by 2
Understanding in vivo modelling of depression
Bannach‐Brown, A. (2019) · ERA · Cited by 1
S-adenosyl methionine (SAM-e) for depression in adults
Galizia, I., Oldani, L., Macritchie, K., Amari, E., Dougall, D., Jones, T. N., Lam, R. W. M., Massei, G. J., Yatham, L. N., & Young, A. H. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011286 · Cited by 2
Berger, T., van Calker, D., Brakemeier, E., & Schramm, E. (2015) · Elsevier eBooks · doi:10.1016/b978-3-437-22484-3.00011-6 · Cited by 1
Baghai, T. C., Blier, P., Baldwin, D. S., Bauer, M., Fountoulakis, K. Ν., Kasper, S. F., Leonard, B. E., Stein, D. J., & Versiani, M. (2011) · Cited by 1
Berger, T., van Calker, D., Brakemeier, E., & Schramm, E. (2012) · Elsevier eBooks · doi:10.1016/b978-3-437-22483-6.10011-7 · Cited by 1
Laux, G. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_67 · Cited by 2
Koyuncu, A., Binbay, Z., Ertekin, E., & Sağır, S. (2013) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.5455/cap.20130518 · Cited by 1
Comment to “Requiem or resurrection: Classic monoamine oxidase inhibitors revisited”
Birkenhäger, T. K., & Ruhé, H. G. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.07.001 · Cited by 1
Fagiolini, A. M., Amodeo, G., & Maina, G. (2017) · doi:10.1093/med/9780198746638.003.0010 · Cited by 1
Teal, L. B., Ingram, S., Bubser, M., McClure, E. W., & Jones, C. K. (2023) · Advances in neurobiology · doi:10.1007/978-3-031-21054-9_3 · Cited by 2
Antidepressant-Antianxiety Agents
Baldessarini, R. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3710-9_4 · Cited by 1
Depressive Disorders: Major Depressive Disorder and Persistent Depressive Disorder
MacKinnon, D. F. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch50 · Cited by 2
Heleniak, C. M., Kaur, T., Ghalib, K., & Rynn, M. A. (2012) · Wiley eBooks · doi:10.1002/9781119958338.ch7 · Cited by 1
Depressive Kernsymptome : Wirksamkeit medikamentöser antidepressiver Therapieverfahren
Damm, J., Eser, D., Schüle, C., Möller, H.-J., Rupprecht, R., & Baghai, T. C. (2009) · Der Nervenarzt · Cited by 1
Schwertfeger, N., Regen, F., Szegedi, A., & Benkert, O. (2011) · Springer eBooks · doi:10.1007/978-3-642-19844-1_76
Biomarkers and Surrogate Markers in Drug Development
Cutler, N. R., Sramek, J. J., Murphy, M. F., Riordan, H., Bieck, P. R., & Carta, A. (2010) · Wiley eBooks · doi:10.1002/9781444318579.ch4
Cognitive-Behavioural Therapy Combined with Antidepressants for Major Depressive Disorder
Maneeton, N. (2012) · InTech eBooks · doi:10.5772/30340
DFP: Antidepressive Pharmakotherapie: Aktueller Stand und neue Entwicklungen
Baghai, T., Hp, V., & Hj, M. (2017) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Unipolare Depression–Pharmakitherapie und Psychotherapie (ICD-10 F3)
Schmauß, M., Schramm, E., & Berger, T. (2008) · Elsevier eBooks · doi:10.1016/b978-343724780-4.50011-7
Zirngibl, C. (2014) · Journal of Depression & Anxiety · doi:10.4172/2167-1044.1000154
Melancholic Depression and its Relationship to Cognitive Decline
Corsentino, E. A. (2010)
SP ZOZ MSW im. prof. L. Bierkowskiego
Buzuk, G. (2014)
Oxford American Psychiatry Library: Major Depressive Disorder
Abbott, C. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010049
The Persona of Ingmar Bergman: Conquering Demons Through Film
Guillemet, I., & Davies, R. D. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010121
The Psychiatric Interview in Clinical Practice, Third Edition
Freedman, R. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16020233
Reducing the Time and Effort Required by Meta-Analysis through the Use of Random Sampling
DuVernet, A. M. (2008) · NCSU Libraries Repository (North Carolina State University Libraries)
Monoamine Oxidase-A in Borderline Personality Disorder and Antisocial Personality Disorder
Kolla, N. J. (2015) · TSpace (University of Toronto)
McLaughlin, P., & Cleare, A. J. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.009
Monoamine Oxidase Inhibitors in Depressive Disorders
Meyer, J. H., Matveychuk, D., Holt, A., Santhirakumar, A., & Baker, G. B. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_98-1
Pérez, P., & Arenaza, J. G. (2014) · Springer eBooks · doi:10.1007/978-3-319-05870-2_23
Laux, G. (2016) · Springer eBooks · doi:10.1007/978-3-642-45028-0_67-1
Laux, G. (2011) · Springer eBooks · doi:10.1007/978-3-642-03637-8_55
Perez-Parada, J. (2014) · Springer eBooks · doi:10.1007/978-3-642-27772-6_7041-1
Laux, G. (2008) · Springer eBooks · doi:10.1007/978-3-540-33129-2_55
Perez-Parada, J. (2015) · Springer eBooks · doi:10.1007/978-3-642-36172-2_7041
Don’t overlook monoamine oxidase inhibitors in psychiatric practice
Fenton, C., & Lee, A. (2022) · Drugs & therapy perspectives · doi:10.1007/s40267-022-00917-7
Anxiety-depressive disorders in obese patients
Velychko, V. I., Lahoda, D. O., & Danylchuk, G. (2022) · Diabetes Obesity Metabolic Syndrome · doi:10.57105/2415-7252-2022-5-03
(2016) · Wiley eBooks · doi:10.1002/9781394259472.refs
Drug and Physical Treatments of Depression
Williams, R. C., & Cleare, A. J. (2024) · Cambridge University Press eBooks · doi:10.1017/9781911623861.006
Chapter 48. Treatment of Depression
Collier, S. J., & Nemeroff, C. B. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as48
Grundlagen der Diagnostik und Therapie
(2024) · Elsevier eBooks · doi:10.1016/b978-3-437-22487-4.16001-0
Tricyclic antidepressants for treatment-resistant depression
Bobo, W. V., & Richelson, E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00008-6
Kundu, S. R., & Sarkar, J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33112-1.00004-5
Carmellini, P., Cuomo, A., Rescalli, M. B., Pinzi, M., Dourmas, A., & Fagiolini, A. M. (2026) · Pharmaceuticals · doi:10.3390/ph19050662
Biological heterogeneity of melancholic, atypical, anxious, and psychotic depression
Nadei, O. V., & Ternovaya, E. V. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111923
Metadata
- Authors
- Henkel, V., Mergl, R., Allgaier, A.-K., Kohnen, R., Möller, H.-J., & Hegerl, U.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Corresponding author
- Mergl, Roland
- Venue
- Psychiatry Research
- Publisher
- Elsevier BV
- Published
- 2006-01
- Volume
- 141
- Issue
- 1
- Pages
- 89-101
- ISSN
- 0165-1781 (ISSN-L)
- OpenAlex
- W1986750404
- Cited by
- 161
- References
- 99
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 9 · 2023: 6 · 2022: 8 · 2021: 5 · 2020: 4 · 2019: 6 · 2018: 2 · 2017: 10 · 2016: 10 · 2015: 13 · 2014: 9 · 2013: 8 · 2012: 13
- FWCI
- 0.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychiatry Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- atypical depression, major depressive disorder, monoamine oxidase inhibitors, antidepressant treatment, selective serotonin reuptake inhibitors, tricyclic antidepressants, placebo comparison, treatment efficacy
- MeSH terms
- Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Humans, Monoamine Oxidase Inhibitors, Phenelzine, Severity of Illness Index, Sertraline, Moclobemide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
